Quantcast
Last updated on April 16, 2014 at 17:25 EDT

Latest epigenomics Stories

DNA Methylation May Increase Cancer Risk As We Age
2014-02-04 05:01:25

redOrbit Staff & Wire Reports - Your Universe Online Age-related changes in a biochemical process known as DNA methylation could be responsible for the increased risk of cancer in older men and women, according to research appearing in the latest edition of the journal Carcinogenesis. While medical experts have long known that the aging process is a leading risk factor for the development of several different types of cancer, the exact reasons for that phenomenon have remained...

2014-01-10 08:23:09

NEW YORK, Jan. 10, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Epigenomics AG (OTCQX: EPGNY; Frankfurt Stock Exchange: ECX, Prime Standard), a German-American molecular diagnostics company developing and commercializing products for cancer screening and diagnosis, has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace with qualified...

2013-12-11 12:26:52

DALLAS, December 11, 2013 /PRNewswire/ -- The recent discovery of miRNA and its wide applicability have sparked off a lot of interest among researchers as well as commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of miRNA in diverse fields such as Cancer, Asthma, Heart Disorders, Diabetes, Hepatitis, etc. Bharat Book Bureau is proud to present the report; "Global miRNA Market Outlook to...

2013-11-15 23:20:23

In 2005, the launch of next-generation sequencing technologies radically changed the structure of the biotechnology industry. Since then, the costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests and pave the way for new opportunities in clinical applications. Wellesley, Mass (PRWEB) November 15, 2013 In 2005, the launch of next-generation sequencing technologies radically changed the...

2013-11-06 12:29:07

DUBLIN, November 6, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/vqj3bn/epigenetics) has announced the addition of the "Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)" [http://www.researchandmarkets.com/research/vqj3bn/epigenetics ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2013-10-25 08:25:05

Epigenetics and comparative genomics will be studied with Irys to advance biomedical research SAN DIEGO, BEIJING, and TEL AVIV, Israel, Oct. 25, 2013 /PRNewswire/ -- BioNano Genomics announced today the purchase of two Irys(TM )Systems to be placed at the Chinese Academy of Sciences in Beijing and the School of Chemistry at the Tel Aviv University in Tel Aviv, Israel. These new placements are designed to run the recently released high-throughput chip, IrysChip(TM )V2, which supports...

2013-10-07 23:24:06

The global market for sample preparation reagents and products used in life science research was valued at $4.6 billion in 2012 and is expected to reach $5.4 billion by 2013. BCC Research projects the market to grow to $11.5 billion in 2018, and register a five-year compound annual growth rate (CAGR) of 16.3% from 2013 to 2018. Wellesley, MA (PRWEB) October 07, 2013 According to a new technical market research report, Sample Preparation in Genomics, Proteomics and Epigenomics: Global...

2013-10-02 08:29:09

Irys System provides deeper insights into genome variation for biomedical research and clinical genomics SAN DIEGO, Oct. 2, 2013 /PRNewswire/ -- BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the Irys(TM) System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing. "BioNano Genomics has made significant progress in...

2013-10-01 10:12:53

By detailing a process required for repairing DNA breakage, scientists at the Duke Cancer Institute have gained a better understanding of how cells deal with the barrage of damage that can contribute to cancer and other diseases. The insights, reported online the week of Sept. 30, 2013, in the journal Proceedings of the National Academy of Sciences, build on earlier work by the research team and identify new prospects for developing cancer therapies. The researchers have focused on a...

2013-09-30 08:30:18

CAMBRIDGE, Mass., Sept. 30, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in October: -- Leerink Swann Rare Disease Roundtable at Le Parker Meridien in New York on Wednesday, October 2 at 3:40 p.m. EDT. A live webcast will be available at this link or by visiting the...